China Isotope & Radiation issues supplemental disclosure on Nuclear Medicine Development Center valuation, forecasts

• China Isotope & Radiation issued a supplemental disclosure on its connected transaction to add valuation inputs for its Nuclear Medicine Development Center.
• Appraised value set at RMB 18.4 million as of Sept. 30, 2025, versus net assets book value of RMB 4.27 million.
• Appraisal surplus of RMB 14.13 million, implying a 330.9% uplift, driven by an income-based approach reflecting expected earnings capacity.
• Revenue forecast ramps to RMB 639.42 million by 2030, from RMB 94.21 million in 2026; cost forecast rises to RMB 429.85 million by 2030.
• Discount rate set at 11.21% using WACC; cost of equity 12.02%, cost of debt 3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Isotope & Radiation Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12271977), on August 04, 2026, and is solely responsible for the information contained therein.